Therapeutic Asset Ratings

166 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Metformin Parkinson Disease	Tanta University	P3	B (58)
Istradefylline Parkinson Disease	Virginia Commonwealth University	P2	B (58)
Kdt-3594 Parkinson Disease	Kissei Pharmaceutical Co., Ltd.	P2	B (58)
BACILLUS LICHENIFORMIS Parkinson Disease	Beijing Friendship Hospital	P4	B (56)
Bifidobacterium Parkinson Disease	Beijing Friendship Hospital	P4	B (56)
Live Combined Bifidobacterium Parkinson Disease	Beijing Friendship Hospital	P4	B (56)
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules Parkinson Disease	Beijing Friendship Hospital	P4	B (56)
Sls-005 Trehalose Parkinson Disease	Neuromed IRCCS	P4	B (56)
Ent-01 Parkinson Disease	Enterin Inc.	P2	B (56)
FILGRASTIM Parkinson Disease	University of Nebraska	P2	B (56)
Lenrispodun Parkinson Disease	Intra-Cellular Therapies, Inc.	P2	B (56)
Bezisterim Parkinson Disease	BioVie Inc.	P2	CCC (55)
IZAFLORTAUCIPIR Parkinson Disease	Michael J. Fox Foundation for Parkinson's Research	P2	CCC (55)
Risvodetinib Parkinson Disease	ABLi Therapeutics, Inc.	P2	CCC (55)
ucb0022 Parkinson Disease	UCB Biopharma SRL	P2	CCC (55)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- Parkinson Disease	Ruijin Hospital	P3	CCC (54)
Biib122 Parkinson Disease	Denali Therapeutics Inc.	P3	CCC (54)
FALLYPRIDE Parkinson Disease	Ruijin Hospital	P3	CCC (54)
Dalzanemdor Parkinson Disease	Supernus Pharmaceuticals, Inc.	P2	CCC (54)
Dfn-15 Parkinson Disease	Tanta University	P2	CCC (53)
Alpha Tocopherol Parkinson Disease	Medipol University	P3	CCC (52)
FUROSEMIDE Parkinson Disease	University of Alberta	P3	CCC (52)
Bia 28-6156 Parkinson Disease	Bial R&D Investments, S.A.	P2	CCC (52)
gt-02287 Parkinson Disease	Gain Therapeutics, Inc.	P2	CCC (52)
Human Dopaminergic Progenitor Cells Parkinson Disease	iRegene Therapeutics Co., Ltd.	P2	CCC (52)

Showing 26 to 50 of 166 assets

PreviousPage 2 of 7Next